We rank companies based on fund manager, research analyst and news sentiment
ALC

Alcon
ALC

$82.22
1.15%
 

About: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Employees: 25,315

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 16 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

10% more capital invested

Capital invested by funds: $16.6B [Q3] → $18.2B (+$1.6B) [Q4]

3.68% more ownership

Funds ownership: 44.03% [Q3] → 47.72% (+3.68%) [Q4]

6% more call options, than puts

Call options by funds: $160M | Put options by funds: $151M

0% more funds holding in top 10

Funds holding in top 10: 16 [Q3] → 16 (+0) [Q4]

0% less funds holding

Funds holding: 584 [Q3] → 583 (-1) [Q4]

1% less first-time investments, than exits

New positions opened: 70 | Existing positions closed: 71

11% less repeat investments, than reductions

Existing positions increased: 180 | Existing positions reduced: 203

Research analyst outlook

16 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$65
21%
downside
Avg. target
$91
11%
upside
High target
$100
22%
upside

16 analyst ratings

15 positive
94%
neutral
0%
negative
6%
Goldman Sachs
Richard Felton
22%upside
$100
Buy
Initiated
10 Apr 2024
Stifel
Thomas Stephan
16%upside
$95
Buy
Reiterated
13 Mar 2024
Argus Research
John Staszak
22%upside
$100
Buy
Maintained
4 Mar 2024
Mizuho
Anthony Petrone
22%upside
$100
Buy
Maintained
1 Mar 2024
Keybanc
Brett Fishbin
12%upside
$92
Overweight
Maintained
29 Feb 2024

Financial journalist opinion